Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 5/20 | 1.00 |
| ▸ | ESR2 | Q92731 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | G6PD | P11413 | 1/20 | 1.00 |
| ▸ | PKM | P14618 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 1.00 |
| ▸ | DAB2IP | Q5VWQ8 | 1/20 | 1.00 |
| ▸ | ADCY10 | Q96PN6 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.84 |
| ▸ | SHBG | P04278 | 2/20 | 0.82 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.78 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12027476 | 1.00 | ESR1 (1.00) | ESR1ESR2MEN1LMNAKMT2A | |
| SCHEMBL6010005 | 1.00 | ESR1 (1.00) | ESR1ESR2MEN1LMNAKMT2A | |
| SCHEMBL13123058 | 1.00 | ESR1 (1.00) | ESR1ESR2MEN1LMNAKMT2A | |
| SCHEMBL29565170 | 1.00 | ESR1 (1.00) | ESR1ESR2MEN1LMNAKMT2A | |
| SCHEMBL15491309 | 1.00 | ESR1 (1.00) | ESR1ESR2MEN1LMNAKMT2A | |
| SCHEMBL225053 | 1.00 | ESR1 (1.00) | ESR1ESR2MEN1LMNAKMT2A | |
| SCHEMBL4206797 | 0.91 | CYP19A1 (1.00) | ESR1ESR2MEN1LMNAKMT2A | |
| SCHEMBL2617357 | 0.91 | CYP19A1 (1.00) | ESR1ESR2MEN1LMNAKMT2A | |
| SCHEMBL3868013 | 0.91 | CYP19A1 (1.00) | ESR1ESR2MEN1LMNAKMT2A | |
| SCHEMBL5025553 | 0.91 | CYP19A1 (1.00) | ESR1ESR2MEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 934 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121577774-A | Non-alcoholic fatty liver biomarker composition and application thereof | 西安交通大学医学院第一附属医院 | 2026-02-27 | — | — | CN | claimed |
| WO-2024259428-A2 | ESTROGENIC COMPOUNDS AND FORMULATIONS FOR GESTATION-RELATED COMPLICATIONS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-12-19 | — | — | WO | claimed |
| CN-117789993-B | Establishment and application of gastric cancer prediction model based on tongue fur metabolite | 浙江省肿瘤医院 | 2024-06-11 | — | — | CN | claimed |
| CN-117789993-A | Establishment and application of gastric cancer prediction model based on tongue fur metabolite | 浙江省肿瘤医院 | 2024-03-29 | — | — | CN | claimed |
| US-20240093191-A1 | COMPOSITIONS AND METHODS FOR TREATING DISEASE ASSOCIATED WITH DUX4 OVEREXPRESSION | RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL (US) | 2024-03-21 | — | — | US | claimed |
| EP-4288539-A1 | COMPOSITIONS AND METHODS FOR TREATING DISEASE ASSOCIATED WITH DUX4 OVEREXPRESSION | Research Institute at Nationwide Children's Hospital (US) | 2023-12-13 | — | — | EP | claimed |
| WO-2023234790-A1 | APPLICATION OF HYDROGEN PEROXIDE AND 17β-ESTRADIOL AND ITS METABOLITES AS BIOMARKERS IN A METHOD OF DIAGNOSING NEURODEGENERATIVE DISEASES IN VITRO | GDANSKI UNIWERSYTET MEDYCZNY (PL) | 2023-12-07 | — | — | WO | claimed |
| US-20230210870-A1 | METHODS OF TREATING FEMALE HEALTH CONDITIONS RELATED TO SEX HORMONES | ELIEM THERAPEUTICS INC (US) | 2023-07-06 | — | — | US | claimed |
| EP-4161530-A1 | METHODS OF TREATING FEMALE HEALTH CONDITIONS RELATED TO SEX HORMONES | Eliem Therapeutics (UK) Ltd (GB) | 2023-04-12 | — | — | EP | claimed |
| EP-4021369-A1 | MEDICAL DEVICES FOR CONTINUOUS DELIVERY OF THERAPEUTIC AGENTS | Forman, Mervyn B. (US) | 2022-07-06 | — | — | EP | claimed |
| EP-0923376-A4 | TREATMENT OF ASTHMA AND AIRWAY DISEASES | AMRAD OPERATIONS PTY LTD (AU) | 2001-09-26 | — | — | EP | claimed |
| US-6200966-B1 | FOR TREATING CHRONIC AND ACUTE INFLAMMATION OF AIRWAYS, INCLUDING ASTHMATIC CONDITIONS | AMRAD OPERATIONS PTY. LTD. (AU) | 2001-03-13 | — | — | US | claimed |
| WO-2001014405-A2 | METHODS OF OBTAINING 2-METHOXYESTRADIOL OF HIGH PURITY | ENTREMED, INC. (US) | 2001-03-01 | — | — | WO | claimed |
| JP-2000507923-A | — | — | 2000-06-27 | — | — | JP | claimed |
| US-5962445-A | Treatment of asthma and airway diseases | AMRAD OPERATIONS PTY LTD. (AU) | 1999-10-05 | — | — | US | claimed |
| EP-0923376-A1 | TREATMENT OF ASTHMA AND AIRWAY DISEASES | Amrad Operations Pty.,Ltd. (AU) | 1999-06-23 | — | — | EP | claimed |
| WO-1999001142-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING AN ANGIOSTATIC STEROID COMBINED WITH A HYALURONAN | HYAL PHARMACEUTICAL CORPORATION (CA) | 1999-01-14 | — | — | WO | claimed |
| WO-1997042958-A1 | TREATMENT OF ASTHMA AND AIRWAY DISEASES | AMRAD OPERATIONS PTY. LTD. (AU) | 1997-11-20 | — | — | WO | claimed |
| US-5521168-A | TREATING GLAUCOMA | ALCON LABORATORIES, INC. (US) | 1996-05-28 | — | — | US | claimed |
| US-4427669-A | 2-HYDROXY-OR 4-HYDROXYESTRADIOL | THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 1984-01-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210870-A1 | METHODS OF TREATING FEMALE HEALTH CONDITIONS RELATED TO SEX HORMONES | SHBG, CYP17A1, NR5A1 | ESR1 37/4885ESR2 23/4885MEN1 1071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.